-
FDA Commissioner Marty Makary defends Replimune’s approval choice
U.S. Food and Drug Administration Commissioner Marty Makary defended himself in a CNBC interview aired Tuesday after months of pressure over the recent drug rejections. The unrelenting heat reached new heights this week with a Bloomberg News report that described “paranoia, turmoil and backlash” at the agency under Makary’s tenure. A Wall Street Journal opinion…
-
Understanding NAD+ Injections and Their Role in Cellular Health and Function
NAD+ injections are being talked about for one simple reason. They go straight at a molecule your body already depends on to produce energy and keep cells functioning. No guesswork about what NAD+ is supposed to do. It’s already part of the system. The question now is whether boosting it, especially through injections, may support…
-
UnitedHealth Group (UNH) Q1 2026 outcomes
UnitedHealthcare’s sign is displayed at its office building in Minnetonka, Minnesota, USA on December 11, 2025. Tim Evans | Reuters UnitedHealth Group on Tuesday reported first-quarter profit that beat estimates and raised its 2026 profit outlook as the company can better manage high medical costs and streamline its operations. The nation’s largest private insurer said…
-
Metformin for Longevity: Understanding Its Anti-Aging Potential
Metformin has been used for decades. Not as a wellness trend. Not as a supplement experiment. As a prescription drug with a long safety record in metabolic disease. What has changed is how researchers now view the drug. Instead of asking only how Metformin lowers blood glucose, the question has widened. Can Metformin support longevity?…
-
Trump is getting ready drug tariffs of as much as 100%
The Trump administration on Thursday imposed new tariffs on brand-name drugs from drug companies that have not reached agreements with the president to lower their U.S. drug prices – a long-awaited move that is likely to affect only a small fraction of drugmakers. “We need to ensure that our drug supply is protected, safe and…
-
Eli Lilly reaches deal to carry AI-developed medication to international market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, November 21, 2025. Mike Blake | Reuters BEIJING – US pharmaceutical giant Eli Lilly has struck a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. According to the…
-
Pfizer’s Lyme illness vaccine fails trial, firm applies for FDA approval
Thomas Fuller | Photo only | Getty Images Pfizer On Monday, the company said it would seek regulatory approval for a Lyme disease vaccine candidate, even though the shot failed in a late-stage trial. Pfizer said the vaccine missed the study’s statistical target because not enough people in the study had Lyme disease to rely…
-
Eating places add protein, fiber for weight reduction drug customers
A mini burger, mini fries and mini beer, Clinton Hall’s “Teeny Weeny Mini Meal”, is pictured next to a regular-sized combo on Dec. 8, 2025 in New York City. Approximately one in eight American adults are currently taking drugs from the class of GLP-1 agonists that are now popular for weight loss, according to a…
-
Eli Lilly shares slide after bearish analyst name – this is our take
Shares of Eli Lilly fell 6% on Tuesday and are on track for their worst day since February after a downgrade by HSBC. The gist of HSBC’s claim: Wall Street is overly optimistic about the size of the GLP-1 obesity market. The company’s analysts expect it to be between $80 billion and $120 billion in…
-
The Vertex kidney drug povetacicept is profitable within the examine for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney disease successfully passed a Phase 3 trial, a key step in the company’s journey to diversify beyond its main cystic fibrosis drugs. The Boston-based drugmaker said Monday…
